期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

延长α-干扰素疗程对HBsAg/抗-HBs血清学转换的影响 被引量：1

下载PDF
导出
摘要 目的探讨延长干扰素疗程对慢性乙型肝炎患者获得HBsAg/抗-HBs应答的可能性。方法 150例慢性乙型肝炎患者给予干扰素-α治疗。常规检测病毒标记物。结果 150例慢性乙型肝炎患者,平均治疗时间为64±34周,有14例(9.3%)患者获得HBsAg/抗-HBs血清学转换;在72例HBeAg阳性患者治疗时间为68±30周,4.2%(3/72)的患者获得HBsAg/抗-HBs应答;78例HBeAg阴性患者治疗时间为69±34周,14.1%(14/78x,2=4.368,P=0.037)的患者获得HBsAg/抗-HBs应答。结论延长干扰素疗程可提高HBsAg/抗-HBs血清学转换率,在HBeAg阴性患者更明显。
作者 江龙中 陈亮
机构地区 安徽省铜陵市有色金属职工总医院感染病科
出处 《实用肝脏病杂志》 CAS 2011年第6期439-440,共2页 Journal of Practical Hepatology
关键词 慢性乙型肝炎 干扰素-Α 治疗 HBSAG
分类号 R512.62 [医药卫生—内科学]
  • 相关文献

参考文献13

  • 1PERRILLO R.Benefits and risks of interferon therapy for hepatitis B[J].Hepatology,2009,49(5 Suppl):S103-111.
  • 2汤伟亮,谢青.慢性乙型肝炎的干扰素治疗[J].中华肝脏病杂志,2009,17(10):726-729. 被引量：10
  • 3CHAN HL,WONG VW,CHIM AM,et al.Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B[J].Aliment Pharmacol Ther,2010,32:1323-1331.
  • 4BRUNETTO MR,MORICONI F,BONINO F,et al.Hepatitis B virus surface antigen levels:a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B[J].Hepatology,2009,49:1141-1150.
  • 5中华医学会传染病与,寄生虫病学分会,肝病学分会.病毒性肝炎防治方案[J].中华肝脏病杂志,2000,8(6):324-329. 被引量：14010
  • 6ANAND AC,PURI P.Treatment of chronic hepatitis B:will entecavir and telbivudine do the trick[J].Trop Gastroentero1,2008,29:71-75.
  • 7European Association For The Study Of The Liver.EASL clinical practice guidelines:management of chronic hepatitis B[J].J Hepatol,2009,50:227-242.
  • 8SYPSA VA,MIMIDIS K,TASSOPOULOS NC,et al.A viral kinetic study using pegylated interferon alfa-2b and/or lamivudine in patients with chronic hepatitis B/HBeAg negative[J].Hepatology,2005,42:77-85.
  • 9LEWIN SR,RIBEIRO RM,WALTERS T,et al.Analysis of hepatitis B viral load decline under potent therapy:complex decay profiles observed[J].Hepatology,2001,34:1012-1020.
  • 10CHEONG JY.Management of chronic hepatitis B in treatment naive patients[J].Korean J GastroenteroJ,2008,51:338-345.

二级参考文献14

  • 1Perrillo R. Benefits and risks of interferon therapy for hepatitis B. Hepatology, 2009, 49(5 Suppl):S 103-111.
  • 2Cootksley WG, Piratvisuth T, Lee SD, et al. Peginterferon alpha-2a (40kDa): an advance in the treatment of hepattitis B e antigen-positive chronic hepatitis B. J Viral Hepat, 2003, 10: 298-305.
  • 3Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic heaptitis B. N Engl J Meal, 2005, 352: 2682-2695.
  • 4Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med, 2004, 351: 1206-1217.
  • 5Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg- positive chronic hepatitis B: a randomised trial. Lancet, 2005, 365: 123-129.
  • 6European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol, 2009, 50: 227-242.
  • 7Bonino F, Marcellin P, Lau GKK, et al. Predicting response to peginterferon-2a, lamivudine and the two combined for HBeAgnegative chronic hepatitis B. Gut, 2007, 56: 699-705.
  • 8Fried MW, Piratvisuth T, Lau GK, et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg positive chronic hepatitis B. Hepatology, 2008, 47: 428-434.
  • 9Buster EH, Flind HJ, Simsek H, et al. Early HBeAg loss during peginterferon alpha-2b therapy predicts HBsAg loss: results of a long-term follow-up strdy in chronic hepatitis B patients. Am J Gastroenterol, 2009[Epub ahead of print].
  • 10Moucari R, Mackiewicz V, Lada O, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology, 2009, 49: 1151-1157.

共引文献14015

同被引文献1

引证文献1

二级引证文献1

实用肝脏病杂志
2011年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部